Whether BO-112 or other dsRNA analogs would have similar effects on MHC class I and/or other APM components in HNSCC cells, and whether these strategies would actually restore ICB sensitivity in HNSCC, remains unclear. This evidence concerns the gene ANPEP and head and neck squamous cell carcinoma.